Ramantamig (JNJ-79635322): A Trispecific T‑Cell Engager Targeting BCMA and GPRC5D Shows Potent Preclinical Activity in Multiple Myeloma
Highlight
– Ramantamig (JNJ-79635322) is a trispecific T-cell engager directed at BCMA, GPRC5D, and CD3 designed to increase tumor binding avidity and overcome antigen-loss mediated resistance in multiple myeloma (MM).
– In preclinical models, ramantamig produced potent cytotoxicity at sub-nanomolar concentrations, depleted malignant plasma cells in patient ex vivo assays and whole-blood co-cultures, and showed tumor prevention and regression activity in murine xenograft models.
– These data support clinical translation; two phase 1 trials in relapsed/refractory MM (NCT05652335, NCT06768489) are ongoing to evaluate safety, tolerability, pharmacokinetics, and early efficacy.
Background and Unmet Need
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.